0001610717-23-000296.txt : 20230922
0001610717-23-000296.hdr.sgml : 20230922
20230922191250
ACCESSION NUMBER: 0001610717-23-000296
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230920
FILED AS OF DATE: 20230922
DATE AS OF CHANGE: 20230922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROWLAND LLOYD A
CENTRAL INDEX KEY: 0001236395
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 231272755
MAIL ADDRESS:
STREET 1: AMYLIN PHARMACEUTICALS INC
STREET 2: 9360 TOWNE CENTRE DR
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2023-09-20
0001501989
CytomX Therapeutics, Inc.
CTMX
0001236395
ROWLAND LLOYD A
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., STE. 400
SOUTH SAN FRANCISCO
CA
94080
true
General Counsel
false
Common Stock
2023-09-20
4
A
0
15000
0
A
86095
D
Common Stock
2023-09-22
4
S
0
5486
1.3006
D
80609
D
Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
Includes 41,875 restricted stock units.
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
/s/ Lloyd Rowland
2023-09-22